Improving Safety Reporting: Putting the Question First and Choosing the Right Estimator for the Incidence of Treatment‐Emergent Adverse Events
Pharmaceutical Statistics · 2026-11 · 25 (6)
DOI: 10.1002/pst.70146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 13.11.2026. Verfasst von Stefan Englert und 7 weiteren Autor:innen. Beteiligte Einrichtung: Statistical Modeling & Methodology, Johnson & Johnson, Neuss, Germany. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 14 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
The assessment of safety is critical throughout the development of drugs, across all therapeutical areas and indications. For marketing authorization, the common practice is to summarize adverse events (AEs) using incidence proportion (IP): the proportion of participants who experience the AE at least once while being exposed to the treatment of interest. However, IP can be biased, particularly when follow‐up is limited and data are immature or when comparing treatment groups with different efficacy profiles. We introduce two distinct research questions regarding AE incidence. The first, the “while‐on‐treatment” approach quantifies AE incidence observed in routine clinical practice where intercurrent events (IE) such as death or treatment discontinuation may occur. The second, the “hypothetical” approach quantifies AE incidence under a counterfactual scenario where all participants remain exposed to treatment. These research questions differ in how intercurrent events are handled and therefore require different analytic approaches. Using a simulation study that mimics a typical early‐development oncology setting, we compared four estimators under heterogeneous follow‐up, varying frequencies and timing of intercurrent events, and both constant and time‐varying AE hazards: IP, Aalen–Johansen (AJ), one minus Kaplan–Meier (1–KM), and probability transformed incidence density (PTID). Our results indicate that AJ performs best for the while‐on‐treatment research question. For a hypothetical research question, PTID is recommended due to its higher precision but can be biased when hazards vary over time. The 1–KM estimator is unbiased for the hypothetical research question but tends to be less precise in small samples. Putting the research question first and selecting the adequate estimator is essential for valid AE reporting to improve interpretability and to reduce bias when characterizing AE incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Statistical Modeling & Methodology, Johnson & Johnson, Neuss, Germany.
- Statistics & Decision Sciences, Johnson & Johnson, High Wycombe, UK.
- Statistics & Decision Sciences, Johnson & Johnson, Allschwil, Switzerland.
- Novartis, Basel, Switzerland.
- Statistics & Decision Sciences, Johnson & Johnson, Hyderabad, India.
- Statistics & Decision Sciences, Johnson & Johnson, Beerse, Belgium.
ORCID-Profile: Stefan Englert, Zoe Craig, Nicolas Sauvageot, Anirban Mitra, Leen Slaets
Zitieren
APA
Englert, S., Craig, Z., Sauvageot, N., Jehl, V., Mitra, A., Gilbert, J., Di Scala, L., & Slaets, L. (2026). Improving Safety Reporting: Putting the Question First and Choosing the Right Estimator for the Incidence of Treatment‐Emergent Adverse Events. Pharmaceutical Statistics, 25(6). https://doi.org/10.1002/pst.70146
Vancouver
Englert S, Craig Z, Sauvageot N, Jehl V, Mitra A, Gilbert J, et al. Improving Safety Reporting: Putting the Question First and Choosing the Right Estimator for the Incidence of Treatment‐Emergent Adverse Events. Pharmaceutical Statistics. 2026;25(6). doi:10.1002/pst.70146
BibTeX
@article{Englert2026,
author = {Englert, Stefan and Craig, Zoe and Sauvageot, Nicolas and Jehl, Valentine and Mitra, Anirban and Gilbert, Jane and Di Scala, Lilla and Slaets, Leen},
title = {Improving Safety Reporting: Putting the Question First and Choosing the Right Estimator for the Incidence of Treatment‐Emergent Adverse Events},
journal = {Pharmaceutical Statistics},
year = {2026},
volume = {25},
number = {6},
doi = {10.1002/pst.70146}
}
EUVIMED